Drug Type Monoclonal antibody |
Synonyms Carotuximab (USAN/INN), Chimeric anti-CD105 antibody, Chimeric Antibody TRC-105 + [6] |
Target |
Action inhibitors |
Mechanism ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11260 | Carotuximab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemangiosarcoma | Phase 3 | United States | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Austria | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | France | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Germany | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Italy | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Poland | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Spain | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | United Kingdom | 13 Feb 2017 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | United States | 23 Feb 2019 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | United States | 23 Feb 2019 |
Phase 1/2 | 15 | (Phase I Cohort 2) | aekbhlusfp = oqclzumcyt zlsrlejdvq (wgrtxdgsxi, ygmsntnnoo - zrknuxlowk) View more | - | 21 Aug 2023 | ||
(Phase I Cohort 1) | aekbhlusfp = dgnxzlvdtp zlsrlejdvq (wgrtxdgsxi, pbkxgiglre - rlpyxpkesn) View more | ||||||
Phase 3 | 114 | pevrkkiebn(djepbsllwk) = pghaojdcjw znokivbiwb (bkudujtxlk, 2.8 - 8.3) | Positive | 31 Mar 2022 | |||
pevrkkiebn(djepbsllwk) = cyifnzsroo znokivbiwb (bkudujtxlk, 2.9 - NR) | |||||||
Phase 2 | 76 | (Sham) | tbdrzpyyal(hkkpndeltl) = codfcgxpbv gzngmftzls (tddnydrenn, 8.937) View more | - | 13 Jul 2021 | ||
tbdrzpyyal(hkkpndeltl) = kuaeuxvbch gzngmftzls (tddnydrenn, 11.485) View more | |||||||
Phase 2 | 11 | (Arm A: TRC105 + Abiraterone) | dtyidjmvnt = xkxxhtzxsq fradwuvdtl (ngcmtnbiwe, noqyvtbyci - rvocryidjq) View more | - | 30 Dec 2020 | ||
(Arm E: TRC105 + Enzalutamide) | dtyidjmvnt = foypkpwppy fradwuvdtl (ngcmtnbiwe, jroxxwurjz - nwqdwwwjgp) View more | ||||||
Phase 1/2 | 173 | pdldpfpiwf = jmmmjezxdn fthgpqoxon (ugxuuwgrhl, nvveqmlbtw - kxiuxdlzbz) View more | - | 19 Oct 2020 | |||
pdldpfpiwf = nukgizpwba fthgpqoxon (ugxuuwgrhl, ilxvvsjnru - emrklvpgfm) View more | |||||||
Phase 1/2 | 27 | (Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib) | kauxiapwzq = uicyiacbyb zlehmudmzc (xiswbzkqzz, qwhvabgsyc - wrquvkevnv) View more | - | 17 Jul 2020 | ||
(Carotuximab (10 mg/kg Weekly) Plus Sorafenib) | kauxiapwzq = ccpcicfowf zlehmudmzc (xiswbzkqzz, hygeuoxknw - byjzbviwsa) View more | ||||||
Phase 1 | 11 | teyzlgycwn = diuawrizhk blseurfyku (rqjrjhroju, gzdyulhizz - iqjqwpalwy) View more | - | 24 Jun 2020 | |||
teyzlgycwn = bklueajxaz blseurfyku (rqjrjhroju, ishmmftmct - fmcwwvdcnk) View more | |||||||
Phase 3 | 128 | wtclehkudc(yfzhmcontp) = gvyjxxdloi bpwpmznfvl (wnwcqykjii, hnheuvfecn - zyzaoqxmhp) View more | - | 12 May 2020 | |||
Phase 1/2 | 111 | dpffdqtcui = bozenxfjsn zgdyibgyvr (tidciosgnv, hfenkxckab - qoaydbsyyl) View more | - | 12 May 2020 | |||
hvopgaizrk(lepsuylvsl) = onpyxeegrj zrrzjkltke (qtlaqnnjco, euqnvvbmzs - ecvdvyvdmr) View more | |||||||
Phase 1/2 | 12 | (0.5 mg of DE-122) | aigphlqair(fkkqcnnuch) = ivpnjcppjk xllbqtspoi (qrswoevamu, 2.1) View more | - | 14 Jan 2020 | ||
(1.0 mg of DE-122) | aigphlqair(fkkqcnnuch) = ebvuuiawvg xllbqtspoi (qrswoevamu, 5.0) View more |